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A prospective comparison of ER, PR, Ki67
and gene expression in paired sequential
core biopsies of primary, untreated breast
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Abstract
Background: Sequential biopsy of breast cancer is used to assess biomarker effects and drug efficacy. The
preoperative “window of opportunity” setting is advantageous to test biomarker changes in response to therapeutic
agents in previously untreated primary cancers. This study tested the consistency over time of paired, sequential
biomarker measurements on primary, operable breast cancer in the absence of drug therapy.
Methods: Immunohistochemistry was performed for ER, PR and Ki67 on paired preoperative/operative tumor
samples taken from untreated patients within 2 weeks of each other. Microarray analysis on mRNA extracted from
formalin fixed paraffin embedded cores was performed using Affymetrix based arrays on paired core biopsies
analysed using Ingenuity Pathway Analysis (IPA) and Gene Set Analysis (GSA).
Results: In 41 core/resection pairs, the recognised trend to lower ER, PR and Ki67 score on resected material was
confirmed. Concordance for ER, PR and Ki67 without changing biomarker status (e.g. ER+ to ER-) was 90, 74 and
80 % respectively. However, in 23 paired core samples (diagnostic core v on table core), Ki67 using a cut off of 13.
25 % was concordant in 22/23 (96 %) and differences in ER and PR immunohistochemistry by Allred or Quickscore
between the pairs did not impact hormone receptor status. IPA and GSA demonstrated substantial gene expression
changes between paired cores at the mRNA level, including reduced expression of ER pathway analysis on the
second core, despite the absence of drug intervention.
Conclusions: Sequential core biopsies of primary breast cancer (but not core versus resection) was consistent and
is appropriate to assess the effects of drug therapy in vivo on ER, PR and Ki67 using immunohistochemistry.
Conversely, studies utilising mRNA expression may require non-treatment controls to distinguish therapeutic from
biopsy differences.
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Background
Biomarker studies based on the use of core biopsy and/
or resection specimens for translational research in
breast cancer are useful to evaluate effects of therapeutic
intervention in neoadjuvant, pre-surgical and metastatic
studies. Previous studies have sought differences in ER,
PR and HER2 between core biopsies and resected surgical
specimens in primary breast cancer and noted discord-
ance (usually a reduction in expression) ranging from 1.2
to 35 % [1–4]. Concerns remain that core biopsy and sur-
gical specimens may be a source of bias in clinical trials
[5]. The reporting of diagnostic specimens [6] and recom-
mendations for tumor marker prognostic studies [7] are
well established with recommendations in breast cancer
as to the appropriate use of tumor markers [8]. Recently,
Ki67 has come to prominence as a biomarker in breast
cancer of prognostic and predictive potential [9, 10].
In the clinical setting, sequential tumor core biopsy
has become accepted in neoadjuvant and window of op-
portunity studies to seek early evidence of therapeutic
efficacy [11–13]. This has included neoadjuvant endo-
crine trials [14, 15] and novel agents [13] or repurposing
drugs [12, 16] in window of opportunity studies. The
relative simplicity, accessibility and specificity of immu-
nohistochemistry on formalin fixed, paraffin embedded
(FFPE) remains attractive. Trials have identified Ki67 at
2 weeks as a predictor of relapse free survival [14] or
efficacy respectively [17] and as a prognostic marker for
adjuvant chemotherapy [18, 19]. Other studies have
demonstrated changes in gene expression associated with
response to neoadjuvant therapy [20] although signatures
of response to chemotherapy have to date been rare [21].
Based on the suggestion that Ki67 may have prog-
nostic and predictive value, the neoadjuvant Alliance
ALTERNATE trial (NCT01953588) utilises changes in
Ki67 after 1 month of endocrine therapy as a decision
tool for subsequent continuation of endocrine therapy
or switch to chemotherapy in postmenopausal women
with ER positive primary breast cancer. The POETIC
(Peri-operative Endocrine Treatment for Individualising
Care) Trial (CR-UK/07/015) will evaluate the importance
of Ki67 (and other biomarkers) after 2 weeks of treatment
with a non-steroidal aromatase inhibitor in predicting
long-term outcome. These, and other, clinical trials are
predicated on breast cancer biopsy material reflecting
therapeutic effect. However, the consistency of markers ex-
amined by immunohistochemistry [22] and (for premeno-
pausal women) the effect of differences in the endocrine
environment [23] could modify immunohistochemical
and gene expression data (in the absence of therapeutic
intervention) and hence may influence interpretation of
drug efficacy in such settings.
Core biopsy is now considered the tumor sample of
choice for ER, PR and HER2 assessment, given the
excellent fixation possible [24]. The effects of tissue
handling on RNA yield and integrity [25] or comparison
between proteins expressed at the centre or periphery of
breast cancer [26] are established. However, comparative
studies for ER, PR, Ki67 or mRNA expression on paired
core biopsies in the absence of therapeutic intervention
are needed to test for the consistency between sequential
core biopsies and to consider the potential for a wound-
ing effect which might interfere with therapeutic assess-
ment. This study examined paired primary breast cancer
biopsies with a 2 week interval between sampling, using
immunohistochemistry for ER, PR and Ki67 and mRNA
gene expression.
Methods
Immunohistochemistry comparison between core biopsy
and resection specimens
To re-evaluate the consistency of staining between
core biopsy and breast cancer resection specimens, 41
Caucasian women with histologically proven stage I or II
primary breast cancer gave written, informed consent to
participation under the auspices of the Tayside Local Re-
search Ethics Committee (Fig. 1). Patients taking hormone
replacement therapy (HRT) or oral contraception were ex-
cluded; 26 women were postmenopausal and 15 women
premenopausal. FFPE paired biopsies at the time of diag-
nosis (core biopsy) and 2 weeks later at resection (from
the surgical resected specimen taken at pathology cut up)
were examined. The resected tumor was delivered fresh to
the pathology laboratory (in under 30 min), the margins
inked, the specimen sliced at 5–10 mm intervals and fixed
overnight in neutral buffered formalin prior to final dis-
section and block selection. Core biopsies taken at the
time of diagnosis were compared with tissue microarrays
(TMA) made from the resected specimen. For the TMA,
6 × 0.6 mm cores of invasive disease were selected to avoid
prior biopsy sites by a specialist breast pathologist.
No therapeutic intervention occurred between the two
sampling time points.
Immunohistochemistry was performed on 4 μm sec-
tions of FFPE tissues using standard methodologies
[27] using primary antibodies for estrogen receptor
alpha (ER) antibody 6 F11 (1:200; Novocastra Laboratories
Ltd), progesterone receptor (PR) antibody clone 16 (1:800;
Novocastra Laboratories Ltd) and NCL-L-Ki67-MM1
(Anti-Ki67, monoclonal antibody, Leica Microsystems).
Negative controls (lacking primary antibody) were per-
formed for all staining runs.
Samples were scored independently to agreement by
two authors (PGR and LBJ) for an average of the cores
scored- usually all six on the TMA- using the Quick-
score method assessing intensity and proportion (hence
for example 6 × 2 reflects % cells staining x intensity) for
ER, PR [28] and using a cut off of 20 % for Ki67 [9].
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Immunohistochemistry comparison between paired core
biopsies
To eliminate potential tissue handling, fixation and pro-
cessing differences, core biopsies were taken 2 weeks
apart (n = 24) from consenting patients under a separate
Tayside Local Research Ethics Committee permission as
control tissues from a pre-surgical metformin trial [12].
All tissues were placed immediately in neutral buffered
formalin and following overnight fixation processed to
paraffin blocks at a single laboratory.
For the paired cores, immunohistochemistry for ER
and PR was performed as described above and scored
using the Quickscore method [28] and independently
by the Allred method [29]. Immunohistochemistry was
conducted blinded to the clinical data and scored by a
single specialist breast pathologist (LBJ). Following light
microscopy review, slides were scanned into a virtual
microscopy format using an Aperio ScanScope XT TM
(Aperio Technologies, Vista, Ca., USA) at the x40 ob-
jective utilizing standard compression methodology.
The Ki67 index (percentage of nuclear positive cells)
per invasive tumor was calculated using manual annota-
tion of the virtual microscopy slide by means of a
Wacom Bamboo Pen & Touch tablet device (Wacom
Corporation, Saitama Japan) within the WebScope envir-
onment (version 10.2.0.2319) of the Aperio Spectrum
Plus system version 10.2.2.2317. The annotations were
assessed by the Aperio IHC nuclear Algorithm version
10. Only invasive tumor cells were assessed; great care
was taken to exclude normal epithelial, in situ epithe-
lial, stromal and inflammatory elements. A mean 5600
nuclei (range 601–39,788) per invasive tumor was
assessed to obtain the Ki67 index. A minimum of 1000
invasive tumor cells was examined except for one pre-
treatment and one post-treatment core (601 and 825
cells respectively).
RNA Microarray
For RNA microarray analysis, FFPE core biopsy samples
from 12 otherwise unselected patients from the control
arm of a preoperative clinical trial [12] were examined.
These represent 12 pairs of the 24 paired samples from
the immunohistochemistry comparison between paired
core biopsies where there was sufficient tumour material
in the core for RNA extraction and analysisconfirmed
on a Haematoxylin and Eosin slide was confirmed by a
specialist breast pathologist (LBJ). RNA extraction and
Breast Cancer Disease-Specific Array (DSA) gene expres-
sion profiling was performed as previously described [12].
Data were corrected for background noise, summarized
and normalized using RMA in Partek® Genomics Suite™
software, 6.5 beta © 2009 (Partek Inc., St. Louis, MO,
USA). Principle component analysis (PCA) revealed that
the main variance associated with the first principle com-
ponent was array quality. An additional transformation
based in singular value decomposition was performed
to remove this technical variation. The data was sub-
sequently log2 transformed.
Differential gene selection
Reliably detected genes were selected by removing the
probe sets with a variance below the mean global vari-
ance. The genes were then filtered based on fold change
(>1.3 for less stringent and 1.5 for stringent selection)
to select the differentially expressed probe sets between
the second biopsy and the baseline biopsy. A student’s
t-test without multiple testing corrections was per-
formed and significant genes (p-value < 0.05 for less
Fig. 1 Remark diagram of patients and samples
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stringent and p-value < 0.005 for stringent selection) se-
lected for further analysis.
Ingenuity Pathway Analysis (IPA)
Ingenuity Pathway Analysis (IPA) analysis mapped genes
differentially expressed between baseline and follow-up
biopsies to biological pathways using the standard com-
mercial software (IPA, http://www.ingenuity.com)
Gene Set Analysis (GSA)
Gene Set Analysis (GSA) examined whether members of
a particular biological pathway occur toward the top or
the bottom of a rank-ordered gene list including all gene
expression measurements ranked by differential expres-
sion between baseline and second core biopsy. This ana-
lysis takes into account information from members of a
pathway that would not make it to the top most differ-
entially expressed gene list (used for the IPA analysis
above). GSA was performed using the BRB Array Tools
software package (http://linus.nci.nih.gov/BRB-Array-
Tools.html, US NCI Biometrics Branch) for 2987 gene
sets collectively representing most known biological and
metabolic pathways in Gene Ontology (GO, http://
www.geneontology.org). To be included, a GO gene set
required a minimum of 10 and a maximum of 200
genes. Significance was estimated with a permutation
test (n = 1000). The null hypothesis was that the average
degree of differential expression of members of a given
gene set between the baseline and second biopsy was the
same as expected from a random permutation of biopsy
labels. IPA software was used to generate pathway fig-
ures for the significant gene sets.
Table 1 Changes in ER, PR and Ki67 in paired core biopsy/resection specimens (n = 42 women)
Number
of patients
Change from
<4 to ≥4
Change from
≥4 to < 4
Rise of fall in score, but
not crossing threshold 4
No change
between samples
ER premenopausal 15 0 3 4 8
ER postmenopausal 26 0 1 14 11
PR premenopausala 15 1 4 4 6
PR postmenopausala 16 1 3 6 6
Change from
<20 % to ≥20 %
Change from
≥20 % to <20 %
Rise or fall in Ki67, but
not crossing 20 %
No change
between samples
Ki67 premenopausal 15 2 1 8 rise 4
Ki67 postmenopausalb 25 1 4 3 rise + 11 fall 6
Notes
aPR not assessed in the diagnostic core from one premenopausal and nine postmenopausal women
bKi67 not assessed in the diagnostic core from two postmenopausal patients
Fig. 2 Estrogen receptor expression by IHC on sequential specimens (core v resection, left panel, core v core, right panel)
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Results
Comparison between core biopsy and resection specimens
In tumor samples from 41 women (Table 1) there was a
clinically significant change (loss) of ER between the
diagnostic core and the resection specimen in cancers
from 4/41 (10 %) women across the threshold for adjuvant
endocrine therapy of a Quickscore of 4/18, although the
ER score changed in a further 18 women, but would not
change the clinical impact (Fig. 2 and Table 2). Loss of ER
was identified in 3/15 (20 %) premenopausal women and
PR changes occurred in both premenopausal and post-
menopausal women. For Ki67 (Fig. 3), there was also a
loss of staining in assessable samples to below 20 % in 1/
15 (7 %) premenopausal and 4/25 (16 %) postmenopausal
women and a rise above 20 % in 2/15 (14 %) premeno-
pausal and 1/25 (4 %) postmenopausal women; Ki67 was
not assessable on one core.
Immunohistochemistry comparison between paired core
biopsies
In paired core biopsies from 17 women, using the
Quickscore method, in 2/17 (12 %) there was reduced
expression of ER in the second core biopsy and in 3/17
(18 %) increased expression of ER in the second core
(Fig. 2). In none of these five patients would the change
in ER have led to a therapeutically important switch
whether the Quickscore or Allred score was applied.
For PR in 6/17 (35 %) women there was reduced ex-
pression of PR in the second core biopsy and in 3/17
(18 %) increased expression of PR in the second core. In
none of these nine patients would the change in PR have
led to a therapeutically important switch whether the
Quickscore or Allred score was used.
Ki67 was available on 23 paired core biopsies (including
the 17 for ER and PR pairs). Using 20 % as a cut off [9],
5/23 (22 %) tumor samples would have crossed the
20 % threshold between the paired samples: 2/23 (9 %)
patients would have crossed from above to below 20 %
and tumor samples from a further 3/23 (13 %) patients
from below to above 20 %. However, using 13.25 % as the
cut off [10], only 1/23 (4 %) tumors would have crossed
the 13.25 % boundary comparing the two cores (Fig. 3).
RNA microarray
Microarray analysis was successfully completed on all 12
paired samples. By paired t-test differences in gene ex-
pression profile were identified between the diagnostic
and surgical core biopsy.
By GSA (Fig. 4), the differences between the two biop-
sies suggested changes in pathways involving myc, apop-
tosis and p53 amongst others in the second biopsy
compared with the first. Several elements of cellular me-
tabolism and immunological pathways were identified as
overexpressed (Fig. 5a) in the second biopsy as
Table 2 Comparison of ER and PR in paired core biopsies
(n = 23 women)
No
change
Reduced
expression
(no switch)a
Increased
expression
(no switch)a
Switchb Missing
data
ER 17 2 3 0 6
PR 17 6 3 0 6
Notes
aNo switch either by Allred score or Quickscore
bSwitch only using Allred score
Fig. 3 Ki67 expression by IHC on sequential specimens (core v resection, left panel, core v core, right panel)
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compared with the first whereas, the Rho, integrin and
potentially significantly the ER pathways were relatively
underexpressed (Fig. 5b) in the second core biopsy.
IPA set in context a number of gene expression
changes among which pathways involving PI3K, MEKK
and IGF-1 may be of particular relevance in the setting
of breast cancer.
Discussion
Minimising bias in clinical molecular marker studies in
preoperative trials using paired samples is critical to as-
sess the efficacy and target effects of endocrine agents
(for example the ALTERNATE and POETIC trials),
novel therapy [13] or new indications for established
drugs [12] and to change clinical management, at least
in the trial setting (ALTERNATE).
Immunohistochemistry comparison between core biopsy
and resection specimens
To date there have been multiple comparisons of core
biopsies and surgical resections for ER, PR, Ki67 for
tumor grade and HER2 (Table 3) demonstrating a
mean concordance of 92.4 % for ER (Fig. 6a), 84 %
for PR (Fig. 6b) and 67.4 % for Ki67 (Fig. 6c),
d
et
ai
d
e
M
c
y
M
A
p
o
p
to
s
is
 S
ig
n
a
lin
g
A
c
ti
n
 C
y
to
s
k
e
le
to
n
 
S
ig
n
a
lin
g
N
u
c
le
o
ti
d
e
 E
x
c
is
io
n
 
R
e
p
a
ir
 P
a
th
w
a
y
R
a
c
 S
ig
n
a
lin
g
F
A
K
 S
ig
n
a
lin
g
G
ly
c
in
e
, 
S
e
ri
n
e
 a
n
d
 
T
h
re
o
n
in
e
 M
e
ta
b
o
lis
m
1
4
-3
-3
-m
e
d
ia
te
d
 
S
ig
n
a
lin
g
C
C
R
3
 S
ig
n
a
lin
g
 in
 
E
o
s
in
o
p
h
ils
In
te
g
ri
n
 S
ig
n
a
lin
g
p
5
3
 S
ig
n
a
lin
g
0
.0
0
.5
1
.0
1
.5
2
.0
2
.5
3
.0
First vs 
second core 
biopsy
Threshold 
P=0.05 
-L
o
g
 (
P
-v
a
lu
e
)
Fig. 4 Cell pathways associated altered between sequential core biopsies
Overexpression in post wounding Underexpression in post woundinga b
Fig. 5 Cellular pathways associated with wounding effect by GSA. Cell pathways (a) overexpressed between sequential core biopsies and
(b) underexpressed between sequential core biopsies
Hadad et al. BMC Cancer  (2016) 16:745 Page 6 of 11
comparable to the data presented here. Reporting
comparisons between ER, Ki67 and other biomarkers
in this setting may be potentially misleading for well-
rehearsed reasons [1, 5, 30] minimised by the use of
(paired) core biopsies and consistent tissue handling.
We revisited whether the changes in ER might be
secondary to changes in circulating estradiol, confirm-
ing plausible evidence for premenopausal women [23],
but likely due to tissue handling and processing at
least in postmenopausal women [1, 5, 25].
Immunohistochemistry comparison between paired core
biopsies
Paired core biopsies of primary breast cancer before/
after drug therapy has become popular [12, 13, 16],
although quality standards for Ki67 have been of con-
cern [9, 10]. In a trial setting [12], variations in specimen
processing, specimen handling, laboratory processing
and immunohistochemical staining and scoring were
minimised, although patient selection (ER positive T1c
and T2 cancers) occurred.
Table 3 Published research articles on concordance between diagnostic core biopsies and surgical specimens for tumour grade,
Ki67, ER, PgR and Her2
Authors Sample size Tumour Grade (%) Ki67 (%) Tumour type (%) ER (%) PgR (%) HER2 (%)
Motamedolshariati et al. (2014) [36] 30 67 100 97 90 93
Munch-Peterson et al. (2014) [37] 89 77 98 84
Loubeyre et al. (2013) [38] 993 98
Dekker et al. (2012) [39] 115 99 96.2
Greer et al. (2012) [40] 165 89 89 93
Lee et al. (2012) [41] 300 98
Li et al. (2012) – meta-analysis [4] 2450 93 85
Ricci et al. (2012) [42] 69 82 95 87 78
Khoury et al. (2011) [43] 176 93 90
Lorgis et al. (2011) [44] 175 75 84 78 98
Arnedos et al. (2009) [3] 336 98 85 99
Park et al. (2009) [45] 104 81 100 99 97 86
Usami et al. (2007) [46] 111 75 83 95 88 88
Cahill et al. (2006) [47] 95 77 98 68 71 60
Burge et al. (2006) [48] 87 77 100 95 89 96
Hodi et al. (2007) [49] 338 99
Badoual et al. (2005) [50] 110 73.1 74 90 89
Usami et al. (2005) [51] 22 80 89 100 95 80
Al Sarakbi et al. (2005) [52] 93 95 89
Mann et al. (2005) [1] 100 86 83 80
Deshpande et al. (2005) [53] 105 75 96
O'Leary et al. (2004) [54] 113 62 59 65
Andrade and Gobbi (2004) [55] 120 59 62 67
Harris et al. (2003) [56] 500 67 58 74
Connor et al. (2002) [57] 44 64 98 82 91
McIntosh et al. (2002) [58] 133 91 84
Sharifi et al. (1999) [59] 79 75 81
Gotzinger et al. (1998) [60] 150 84 100 97 91.3
Jacobs et al. (1998) [61] 56 100 100
Di Loreto et al. (1996) [62] 41 80 76 78 80 90
Dahlstrom et al. (1996) [63] 51 69 78
Baildam et al. (1989) [64] 140 69
Zidan et al. (1997) [65] 26 73 42
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Slight variation of immunohistochemical scoring of ER
and PR between paired cores, potentially attributable to
geographic targeting differences over time, rarely crossed
the boundary for clinical decision making. For Ki67, the
cut point was key: at 20 % [9], 5/23 (22 %) paired tumor
samples would have crossed the threshold, compared with
only 1/23 (4 %) tumors using 13.25 %, in concordance with
expert opinion [10] confirming a Ki67 boundary of 13.25 %
is appropriate when seeking evidence of a drug effect.
While intra-tumoral heterogeneity has been considered
elsewhere [26], the single cores at each time point
may reflect clinical reality in small cancers for window of
opportunity, pre-operative or neoadjuvant trials. Given
the consensus, for a number of tumor types, that needle
biopsy specimens result in reliable immunohistochemistry
[1, 31], this study provides reassurance that immunohisto-
chemical measurement of ER, PR and Ki67 from core bi-
opsy pairs is consistent over 2 weeks.
RNA microarray
By GSA, the changes expression of genes integral to cell
cycle and apoptosis (Fig. 4), overexpression of cellular
metabolism and immunological pathways (Fig. 5a) and
underexpression of cell motility and cell adhesion
(Fig. 5b) suggest that in the time frames of the biopsy,
perturbation of such pathways remains several days after
the initial wounding effect of the first core biopsy. The
reduction in mRNA expression of the ER pathway
(Fig. 5b) following the first biopsy holds potential con-
cern and is in contrast to the only other published study
of eight patients where no change was noted [32]. How-
ever, mRNA changes do not exactly reflect semiquantia-
tive immunohistochemistry and ER mRNA imperfectly
correlates with the level of ER protein expression [33].
The immunohistochemical studies on the same series of
samples reported here provide comfort that for the tech-
nology most widely used in clinical practice (immuno-
histochemistry), ER on a second core biopsy may not be
compromised.
IPA set in context a number of gene expression
changes among which pathways involving PI3K, MEKK
and IGF-1 [34, 35] may be of particular relevance in the
setting of breast cancer.
These microarray data, within the limits of the experi-
mental design, sample numbers and analytical tech-
niques employed, suggest that core biopsy of primary
breast cancer may generate a “wounding” effect evident
on subsequent mRNA analysis. The time course, dur-
ation and variations in gene expression as a consequence
of tumor and patient variability were not assessed within
this study and are clinically challenging to obtain [25].
However, core biopsy may influence the mRNA expres-
sion profile of sequential clinical samples used in clinical
trials and requires careful evaluation.
Conclusions
This study provides reassurance that sequential core bi-
opsy (but not core versus resection) should be an appro-
priate way to assess the effects of drugs on primary tumor
ER, PR and Ki67 (with a cut off of 13.25 %) within the
context of window of opportunity and neoadjuvant trials.
By contrast, mRNA analyses may demonstrate multiple
changes between paired samples reflecting the wounding
effect of core biopsy, which for ER at least is not reflected
at the level of immunohistochemistry. Sequential core bi-
opsy may be used with confidence when seeking evidence
of ER, PR and Ki67 changes in the preoperative setting for
primary breast cancer.
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